Congress should increase oversight and tighten the requirements for the 340B drug discount program to guarantee the appropriate use of its funds, Pembroke Consulting President Adam J. Fein writes. Requiring pharmacies and hospitals to comply with industry standards for determining 340B prescription claims is necessary to increase transparency and reduce abuse, Fein writes. It is time to update the program and help the poorest patients gain access to useful treatments, Fein writes.

Full Story:
Hill, The

Related Summaries